
Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.
Elizabeth Plimack, MD, Director of Genitourinary Clinical Research, Associate Professor, department of hematology/oncology, Fox Chase Cancer Center, discusses the role of nivolumab in kidney cancer.
We now have long-term follow-up data from patients that have been on nivolumab for four to five years, says Plimack. About one-third of patients are still alive at four years.
This long-term benefit occurred in patients regardless of their initial response to therapy and risk group.
Biomarker development is needed, and as well as research regarding adverse events and combination possibilities. A lot can still be learned regarding how nivolumab should be used in kidney cancer, says Plimack.



